iBorn 10 Oct 1954
Sørensen ran Novo Nordisk from 2000 to 2016 under a structure in which the Novo Nordisk Foundation controls the company's votes, shielding it from takeovers and activist pressure. He used that room to keep investing in diabetes and obesity research through lean years, groundwork for the GLP-1 drugs…